Back to All Combinations

KRAS Codon 61/146

Intermediate Prognosis
4.00% Prevalence Level 1 RAS Pathway
Genes Involved
KRAS
Treatment Implications

Less common KRAS mutations. Confirmed anti-EGFR resistance.

Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
Treatments to Avoid
Anti-EGFR
Study References

Extended RAS analysis

Key Statistics
4.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Always test extended RAS panel.
Information

Category: RAS Pathway

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.